We are live on ! Find out more

741 hedge funds and large institutions have $11.6B invested in GSK in 2015 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 323 increasing their positions, 232 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

51% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 41

39% more repeat investments, than reductions

Existing positions increased: 323 | Existing positions reduced: 232

6% more capital invested

Capital invested by funds: $10.9B → $11.6B (+$703M)

2% more funds holding

Funds holding: 729741 (+12)

0% more funds holding in top 10

Funds holding in top 10: 99 (0)

0.05% less ownership

Funds ownership: 4.18%4.13% (-0.05%)

43% less call options, than puts

Call options by funds: $123M | Put options by funds: $215M

Holders
741
Holders Change
+12
Holders Change %
+1.65%
% of All Funds
19.66%
Holding in Top 10
9
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.24%
New
62
Increased
323
Reduced
232
Closed
41
Calls
$123M
Puts
$215M
Net Calls
-$91.6M
Net Calls Change
-$169M

GSK Hedge Fund Activity: Q1 2015 in Review

741 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q1 2015, worth a combined $11.6B — up 6.5% from $10.9B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new GSK positions and 41 closed out — a net gain of 21 holders — while 323 added to existing stakes and 232 trimmed.

The largest buyer was Barclays, adding an estimated $230M. The largest seller was Waddell & Reed Financial, cutting an estimated $201M.

  • 741 institutional investors held GSK (GSK) as of Q1 2015, up from 729 in Q4 2014.
  • Funds reported $11.6B of GSK stock for Q1 2015, up 6.5% quarter-over-quarter.
  • 62 funds opened new GSK positions in Q1 2015 and 41 closed out, a net change of +21 holders.
  • The largest GSK buyer in Q1 2015 was Barclays, an estimated $230M added.
  • The largest GSK seller in Q1 2015 was Waddell & Reed Financial, an estimated $201M sold.

Based on aggregated 13F filings for Q1 2015.